Abstracts tagged "longitudinal studies"

Abstract Number: 1000 • ACR Convergence 2020
Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women
Kazuki Yoshida¹, Jiaqi Wang², Susan Malspeis³, Bing Lu⁴, Lauren C. Prisco³, Lily Martin³, Julia Ford², Karen Costenbader⁵, Elizabeth Karlson² and Jeffrey Sparks⁶, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Personal cigarette smoking has been strongly associated with the risk for developing seropositive RA. Previous studies concerning passive smoking conflict; some suggested that childhood…
Abstract Number: 1851 • ACR Convergence 2020
Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
Benattar Leslie¹, Anna Molto², Laure Gossec³ and Resche Rigon Matthieu⁴, ¹Cochin Hospital, Paris, Paris, Ile-de-France, France, ²Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ³Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁴INSERM (UFR 1153), Saint Louis Hospital, Paris, Paris, France
Background/Purpose: AxSpA is a heterogeneous disease, leading to different treatment and follow-up modalities depending on the presentation, along with other elements (socio-economic, gender, etc..). In a…
Abstract Number: 1094 • ACR Convergence 2020
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Julie Paik¹, Jemima Albayda¹, Eleni Tiniakou¹, Grazyna Purwin¹, Andrew Koenig² and Lisa Christopher-Stine¹, ¹Johns Hopkins University, Baltimore, MD, ²Pfizer Inc, New York City, NY
Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…
Abstract Number: 1874 • ACR Convergence 2020
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Mark Hwang¹, Martin Rozycki², Theresa Arndt², Esther Yi³ and Michael Weisman⁴, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Healthcare claims databases can be used to identify patients with ankylosing spondylitis (AS) prior to diagnosis. This study explores differences in pathways to AS…
Abstract Number: 1160 • ACR Convergence 2020
Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis
Aleksander Lenert¹, T. Shawn Sato², Sedat G Kandemirli¹, Patrick Ten Eyck¹ and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²University of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: To compare bone lesion evolution and bone lesion distribution patterns identified by whole body magnetic resonance imaging (WB-MRI) by treatment intensity in patients with…
Abstract Number: 1938 • ACR Convergence 2020
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹ and Andreas Diamantopoulos², ¹Martina Hansens Hospital, Hosle, Norway, ²Martina Hansens Hospital, Baerum, Norway
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Studies have shown that while the vision loss rates are higher, the relapse…
Abstract Number: 1298 • ACR Convergence 2020
Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort
Maria Schletzbaum¹, Nnenna Ezeh², Trevor McKown³, Shivani Garg⁴ and Christie Bartels⁵, ¹University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, ³William S. Middleton Memorial Veterans Hospital, Madison, WI, ⁴UW Madison, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: While medical comorbidities increase with age, younger age at onset of Systemic Lupus Erythematosus (SLE) has been associated with greater risk of some types…
Abstract Number: 1983 • ACR Convergence 2020
Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Natalie Shiff¹, Peter Shrader², Colleen Correll³, Anne Dennos⁴, Thomas Phillips² and Timothy Beukelman⁵, ¹Florida, Gainesville, FL, ²Duke University, Durham, ³University of Minnesota, Minneapolis, MN, ⁴Duke University, Durham, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To describe data-derived 2-year trajectories of disease activity in patients with recently diagnosed juvenile idiopathic arthritis (JIA) as measured by the clinical Juvenile Arthritis…
Abstract Number: 1299 • ACR Convergence 2020
Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
Daphne Lew¹, Xinliang Huang², Sara Kellahan², Hong Xian³, Seth Eisen⁴ and Alfred Kim⁵, ¹Washington University in St. Louis School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University in St. Louis School of Medicine, St. Louis, ³Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, ⁴Washington University School of Medicine, St Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Almost 40% of patients with SLE have comorbid mental health conditions.1 Though depression is most commonly reported (24% to 30%), many SLE patients also…
Abstract Number: 1312 • ACR Convergence 2020
Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
Gillian Fitzgerald¹, George Tomlinson², Steve Ramkissoon³, Sophie Wojcik⁴, Robert Inman⁵ and Nigil Haroon⁶, ¹Toronto Western Hospital, Toronto, ON, Canada, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴UHN, Montreal, QC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) patients have higher morbidity and mortality compared to healthy controls. Much of this excess disease burden is related to extra-articular manifestations…
Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Mark Siderius¹, Freke Wink¹, Anneke Spoorenberg¹ and Suzanne Arends¹, ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
Abstract Number: 0272 • ACR Convergence 2020
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
Eric Morand¹, Vera Golder², Worawit Louthrenoo³, Shue Fen Luo⁴, Yeong-Jian Wu⁵, Aisha Lateef⁶, Sargunan Sockalingam⁷, Sandra Navarra⁸, Leonid Zamora⁹, Laniyati Hamijoyo¹⁰, Yasuhiro Katsumata¹¹, Masayoshi Harigai¹², Madelynn Chan¹³, Sean O'Neill¹⁴, Fiona Goldblatt¹⁵, Yi-Hsing Chen¹⁶, Yanjie Hao¹⁷, Zhuoli Zhang¹⁷, Jun Kikuchi¹⁸, Tsutomu Takeuchi¹⁹, Chak Sing Lau²⁰, Zhanguo Li²¹, Alberta Hoi²², Mandana Nikpour²³ and Rangi Kandane-Rathnayake², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Monash University, Clayton, Victoria, Australia, ³Chiang Mai University Hospital, Muang, Thailand, ⁴Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Thomas, Manila, Philippines, ¹⁰University of Padjadjaran, Bandung, Indonesia, ¹¹Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴Sydney University, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹⁷Peking University First Hospital, Beijing, China (People's Republic), ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁹Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ²⁰Hong Kong University, Hong Kong, Hong Kong, ²¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ²²Monash University, Melbourne, Victoria, Australia, ²³The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…
Abstract Number: 1451 • ACR Convergence 2020
Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
Michelle Petri¹, Laurence Magder² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 1467 • ACR Convergence 2020
Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
Andre Luquini¹, Yufei Zheng², Hui Xie³, Catherine Backman¹, Pamela Rogers³, Alex Kwok³, Astrid Knight³, Monique Gignac⁴, Dianne Mosher⁵, Linda Li¹, John Esdaile⁶, Carter Thorne⁷ and Diane Lacaille¹, ¹University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, ²Simon Fraser University / Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Institute for Work & Health / University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Arthritis Research Canada, Vancouver, BC, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: Arthritis often leads to presenteeism (decreased at-work productivity) and permanent work disability, the worst occupational outcome of a disease, leading to reduced quality of…

« Previous Page
1
…
7
8
9
10
11
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].